Vertex discontinues sales of Incivek for Hepatitis C in US.
Vertex Pharmaceuticals Incorporated will be discontinuing the sale and distribution of Incivek (telaprevir) in the United States by October 16th, 2014. Incivek is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated, in combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic HCV in adult patients with compensated liver disease.
This decision has been taken in view of available alternative treatments and the diminishing market demand for Incivek. That is, Sovaldi (sofosbuvir) from Gilead Sciences. In the first six months of this year, Incivek sales were just $13.2 million, a 96% drop from $361.4 million during the same period a year earlier.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.